Pretomanid - Global Alliance for TB Drug Development

Drug Profile

Pretomanid - Global Alliance for TB Drug Development

Alternative Names: PA 824

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Global Alliance for TB Drug Development
  • Class 2 ring heterocyclic compounds; Antituberculars; Nitroimidazoles; Oxazines; Phenyl ethers; Small molecules
  • Mechanism of Action Cell wall inhibitors; Nitric oxide stimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 16 Nov 2017 Global Alliance for TB Drug Development plans a phase IIc trial for Tuberculosis (Combination therapy) in August 2018 (NCT03338621)
  • 03 Jul 2017 Discontinued - Phase-I for Tuberculosis (Monotherapy, In volunteers) in USA (PO)
  • 27 Mar 2017 Global Alliance for TB Drug Development plans a phase III trial for Tuberculosis (Combination therapy) (NCT03086486)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top